Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race
Zealand Pharma shares fell 32.53% to 249.10 Danish crowns by mid-morning Friday after new data for its obesity drug petrelintide disappointed investors, erasing about 8.3 billion crowns ($1.3 billion) in market value. A Phase 2 study showed up to 10.7% weight loss over 42 weeks, well below results seen with Eli Lilly’s rival drug. No vomiting or discontinuations due to gastrointestinal side effects were reported.
